Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Change In Payables And Accrued Expense : $5.7 Mil (TTM As of Sep. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Dicerna Pharmaceuticals Change In Payables And Accrued Expense?

Dicerna Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2021 was $-0.1 Mil. It means Dicerna Pharmaceuticals's Accounts Payable & Accrued Expense declined by $0.1 Mil from Jun. 2021 to Sep. 2021 .

Dicerna Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2020 was $8.9 Mil. It means Dicerna Pharmaceuticals's Accounts Payable & Accrued Expense increased by $8.9 Mil from Dec. 2019 to Dec. 2020 .

Dicerna Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Dicerna Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dicerna Pharmaceuticals Change In Payables And Accrued Expense Chart

Dicerna Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

1.10

0.22

13.26

1.05

8.95

Dicerna Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															1.93	-2.55	5.93	2.41	-0.11

Dicerna Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.7 Mil.

Dicerna Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Dicerna Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dicerna Pharmaceuticals Inc (NAS:DRNA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Hayden Avenue, Lexington, MA, USA, 02421

Website

https://www.dicerna.com

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.

Executives

Bob D Brown	officer: See Remarks	87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Shreeram Aradhye	officer: EVP & Chief Medical Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Marc D Kozin	director
Douglas Fambrough	director, officer: President and CEO	C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
James B Weissman	officer: Chief Operating Officer & EVP	C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Regina M. Paglia	officer: Chief Human Resources Officer	C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Robert D. Ciappenelli	officer: Chief Commercial Officer	DICERNA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Stephen K Doberstein	director	129 ELSIE STREET, SAN FRANCISCO CA 94110
Patrick M. Gray	director	C/O CIVITAS SOLUTIONS, INC. 313 CONGRESS STREET, 6TH FLOOR BOSTON MA 02210
J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Martin I Freed	director	87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Stephen J Hoffman	director	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301